FTC releases pay-for-delay study
Thursday, 14 January 2010
Ron Knox
The US Federal Trade Commission yesterday published a study showing that the lack of access to generic drugs caused by reverse settlement payments in the pharmaceutical industry could cost US consumers as much as US$35 billion over 10 years.
The US Federal Trade Commission yesterday published a study showing that the lack of access to generic drugs caused by reverse settlement payments in the pharmaceutical industry could cost US consumers as much as US$35 billion over 10 years.
Subscription required to view this article
This content can only be accessed by GCR subscribers.
A subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current print and online content.
Please note: If you would like online access to all archived content, you will need a Premium subscription.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top